The GABAergic drug baclofen and the cholinergic drug physostigmine were administered to patients with upbeat and downbeat nystagmus. Baclofen (orally, 5 mg three times daily) reduced nystagmus slow phase velocity and distressing oscillopsia by 25-75% in four out of five patients (two upbeat nystagmus; two downbeat nystagmus). Physostigmine (1 mg single intravenous injection) increased nystagmus in five additional patients with downbeat (1) or positional downbeat nystagmus (4) for a duration of 15-20 minutes. The different interactions of baclofen and physostigmine on neurotransmission subserving vertical vestibulo-ocular reflex could account for these effects. The response to baclofen appears to be a GABA-B-ergic effect with augmentation of the physiological inhibitory influence of the vestibulocerebellum on the vestibular nuclei. Similarly baclofen has an inhibitory effect on the velocity storage mechanism.
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Cholinergic action may cause the increment of nystagmus by physostigmine.
Little is known about neurotransmitters involved, although pathways for upward and downward VOR have been identified. Clinical evidence suggests cholinergic and gabaergic transmission. Cholinergic drugs (physostigmine) counteract a hyperactive horizontal VOR and disturbed fixation suppression of caloric nystagmus in familial ataxia" " and cerebellar degeneration. 6 Anticholinergic drugs (scopolamine or trihexiphenidyl) suppress acquired pendular nystagmus and palatal myoclonus. 7 The GABA-B-agonist baclofen effectively suppresses periodic and non-periodic alternating nystagmus. '20 In this report, we describe the effects of baclofen (GABA-B-agonist) and physostigmine (cholinergic drug) in 10 patients with acquired upbeat (2) , downbeat (4), or positional downbeat nystagmus (4) . In one (patient 6), the effect of the anticholinergic drug biperiden, which was injected 10 minutes after physostigmine injection, was tested. It was found that baclofen inhibits upbeat and downbeat nystagmus in some patients and this has obvious clinical relevance. Physostigmine on the other hand, appeared to change the condition for the worse.
Accepted 15 November 1990 Upbeat and downbeat nystagmus Patients 7-10 showed slight downbeat nystagmus, with Frenzel's glasses, in the upright position of the head and positional downbeat nystagmus in the head hanging position. After physostigmine application (1 mg), the increased downbeat nystagmus was recorded in the upright position with the eyes closed. There was no history of previous drug treatment in these patients.
Two healthy male subjects (aged 34 and 29 years respectively) were used as controls. Their eye movements were recorded with electro-oculography (EOG) before and after the intravenous injection of 1 mg physostigmine.
Horizontal and vertical eye position was recorded separately by DC-EOG with a resolution of 1 degree. The servo-controlled chair-drum system rotating about the vertical Z-axis. A servo-controlled laser projection on a half-spherical screen (at a distance of 1-5 m) provided the visual target for guided saccades. The test programme included measuring spontaneous nystagmus with the eyes closed and with the eyes open in the dark, fixation straight ahead, horizontal (up to 400) and vertical (up to 200) gaze. The vestibulo-ocular reflex (VOR) was tested by chair rotation in the light. For suppression of the VOR, the patient fixated on a small target light which moved together with the head. For quantitative evaluation of the suppression of the VOR (VOR-SUPP) the condition, when the patient was rotated in the light without fixating a target, was set 1 (no VOR suppression); a value of 0 was complete suppression of the horizontal VOR by visual fixation (perfect VOR suppression).
EOG recordings were performed before and on the third day of baclofen (3 x 5 mg) treatment (patients 1, 2, 3, 4, 5) as well as before and four to five minutes after intravenous injection of 1 mg physostigmine (patients 6, 7, 8, 9, 10) or 2 mg biperiden (patient 6).
Results
In all patients and conditions the mean slow phase velocity of the nystagmus was measured.
Baclofen treatment 3 x 5 mg (patients 1-5) (table 2) Four patients (1-4) showed a suppression of 50 (25-75)% of the upbeat/downbeat nystagmus in the primary position of gaze and on lateral gaze or upward gaze (fig 1) . In patient 2, the beneficial baclofen effect could be reproduced after termination of the treatment for two days (fig 2) . Patient 5 showed no beneficial effect under baclofen treatment (the increase in the slow phase velocity of the downbeat nystagmus can be explained by clinical progression of the disease).
Physostigmine and biperiden injections (patient 6) (table 3) The downbeat nystagmus on fixation straight ahead (9 0 deg/s) increased for 15-20 minutes after injection of 1 mg physostigmine (24 0 deg/s, fig 3) . The gain for visual horizontal VOR suppression remained constant with 0-56 versus 0 57. (2) Biperiden injection (2 mg; anticholinergic drug), 10 The results of pharmacological studies, however, cannot be simply explained by cholinergic or anticholinergic effects. Thurston et al '6 showed that physostigmine reduced a hyperactive VOR gain (measured in the dark) in a patient with a cerebellar degeneration, whereas neither baclofen nor diazepam were able to modulate VOR gain in this case. One might speculate that cholinergic intensification of the visual input in this particular patient caused the reduction of the hyperactive VOR by long term adaptation. In contrast to this observation, we saw a transient increase of nystagmus amplitude in our downbeat and positional downbeat nystagmus patients following physostigmine application. Nicotine, a cholinergic agent, is probably responsible for the tobacco-induced primary position upbeat nystagmus in normal subjects,283' which may also be explained as a central vestibular tone imbalance rather than an effect on the visual pursuit system. This explanation is consistent with the findings by Sibony et al2930 on horizontal and vertical eye movements in smoking in normal subjects.
There are two possible explanations for the enhancement of downbeat nystagmus by physostigmine injection in our cases. Firstly, a directional imbalance of the vertical VOR causes downbeating nystagmus. A simultaneous increase in the up and down tone by physostigmine induces an absolutely greater tone imbalance between both directions which subsequently enhances downbeat nystagmus. In contrast, there was no pre-existing tone imbalance in the patient with hyperactive VOR described by Thurston et al. ' 
